The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

Trial Details

NCT ID

NCT07138755

Phase

PHASE2

Sponsor

The Third Xiangya Hospital of Central South University

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

• Experimental

Locations (sample)

• Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

• The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study
• Age range of 18-75 years old upon enrollment, both male and female are eligible
• Stage III NSCLC confirmed by histology or cytology (according to the International Union Against Cancer and the Joint American Committee on Cancer …
• It was clarified that surgical resection is not possible After MDT discussion,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.